What is William Blair’s Estimate for Penumbra Q1 Earnings?

Penumbra, Inc. (NYSE:PEN) – Equities research analysts at William Blair decreased their Q1 2025 earnings per share (EPS) estimates for shares of Penumbra in a note issued to investors on Wednesday, April 2nd. William Blair analyst M. Andrew now expects that the company will earn $0.66 per share for the quarter, down from their previous forecast of $0.79. The consensus estimate for Penumbra’s current full-year earnings is $3.67 per share. William Blair also issued estimates for Penumbra’s Q2 2025 earnings at $0.83 EPS, Q2 2025 earnings at $0.83 EPS, Q4 2025 earnings at $1.17 EPS, Q4 2025 earnings at $1.17 EPS, Q1 2026 earnings at $0.99 EPS, Q1 2026 earnings at $0.99 EPS, Q2 2026 earnings at $1.11 EPS, Q3 2026 earnings at $1.30 EPS, Q3 2026 earnings at $1.30 EPS, Q4 2026 earnings at $1.48 EPS, FY2026 earnings at $4.88 EPS and FY2026 earnings at $4.88 EPS.

A number of other brokerages have also recently commented on PEN. Robert W. Baird raised their price target on shares of Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 19th. Truist Financial raised their target price on Penumbra from $285.00 to $325.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Morgan Stanley upped their price target on Penumbra from $240.00 to $260.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 19th. JPMorgan Chase & Co. increased their price objective on Penumbra from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. Finally, Royal Bank of Canada lifted their target price on shares of Penumbra from $285.00 to $313.00 and gave the company an “outperform” rating in a research note on Wednesday, February 19th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $294.47.

Penumbra Price Performance

NYSE:PEN opened at $262.37 on Friday. The company has a market capitalization of $10.11 billion, a price-to-earnings ratio of 771.66, a PEG ratio of 2.83 and a beta of 0.51. The company has a 50-day moving average of $274.48 and a 200-day moving average of $245.21. Penumbra has a 52 week low of $148.00 and a 52 week high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01.

Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.88 by $0.09. The firm had revenue of $315.52 million during the quarter, compared to analysts’ expectations of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new stake in Penumbra in the fourth quarter worth $573,000. State Street Corp raised its stake in Penumbra by 0.3% during the 3rd quarter. State Street Corp now owns 1,236,671 shares of the company’s stock worth $240,298,000 after buying an additional 3,863 shares during the period. E. Ohman J or Asset Management AB raised its stake in Penumbra by 10.4% during the 4th quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company’s stock worth $5,061,000 after buying an additional 2,000 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Penumbra by 1.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company’s stock worth $64,493,000 after acquiring an additional 3,807 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Penumbra by 1.7% in the third quarter. Geode Capital Management LLC now owns 655,572 shares of the company’s stock valued at $127,417,000 after acquiring an additional 11,257 shares during the period. Institutional investors own 88.88% of the company’s stock.

Insider Activity

In other news, Director Thomas Wilder sold 360 shares of the firm’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $264.58, for a total value of $95,248.80. Following the transaction, the director now directly owns 4,533 shares in the company, valued at $1,199,341.14. This trade represents a 7.36 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Adam Elsesser sold 61,600 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $283.59, for a total value of $17,469,144.00. Following the completion of the sale, the chief executive officer now owns 16,376 shares of the company’s stock, valued at $4,644,069.84. This represents a 79.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 111,236 shares of company stock valued at $31,222,390. 5.00% of the stock is currently owned by insiders.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.